重庆医学2024,Vol.53Issue(5) :782-786.DOI:10.3969/j.issn.1671-8348.2024.05.026

BRAF V600E突变非小细胞肺癌患者全程管理的研究进展

Research progress on whole-course management of non-small cell lung cancer patients with BRAF V600E mutation

杨淋 王玉波
重庆医学2024,Vol.53Issue(5) :782-786.DOI:10.3969/j.issn.1671-8348.2024.05.026

BRAF V600E突变非小细胞肺癌患者全程管理的研究进展

Research progress on whole-course management of non-small cell lung cancer patients with BRAF V600E mutation

杨淋 1王玉波1
扫码查看

作者信息

  • 1. 重庆大学附属江津医院呼吸与危重症医学科,重庆 402260
  • 折叠

摘要

肺癌是全球发病及死亡人数最多的恶性肿瘤,其中以非小细胞肺癌(NSCLC)占比最多.鼠类肉瘤病毒癌基因同源物B1(BRAF)是一种原癌基因,与NSCLC的不良预后有关,其中以BRAF V600E突变为代表.近年来,关于BRAF V600E突变NSCLC患者的诊治已成为肺癌精准诊疗研究的焦点,特别是其全程管理备受关注.关于BRAF V600E突变患者的靶向、免疫及化疗等的相关研究层出不穷,该文就国内外相关的研究进展进行综述.

Abstract

Lung cancer is the malignant tumor with the highest incidence and death in the world,among which non-small cell lung cancer(NSCLC)accounts for the largest proportion.The BRAF gene is a proto-on-cogene associated with poor prognosis in NSCLC,represented by BRAF V600E mutations.In recent years,the diagnosis and treatment of NSCLC patients with BRAF V600E mutation has become the focus of accurate di-agnosis and treatment of lung cancer,especially its whole-course management.There are many related studies on targeting,immunotherapy and chemotherapy for patients with BRAF V600E mutation.This paper reviewed the relevant research progress at home and abroad.

关键词

非小细胞肺癌/BRAF/V600E/治疗/全程管理/综述

Key words

non-small cell lung cancer/BRAF V600E/treatment/whole-course management/review

引用本文复制引用

基金项目

重庆市区域医学重点学科项目(zdxk201701)

出版年

2024
重庆医学
重庆市卫生信息中心,重庆市医学会

重庆医学

CSTPCD
影响因子:1.797
ISSN:1671-8348
参考文献量45
段落导航相关论文